Pharmafile Logo

Sandoz Group AG

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Sandoz Group AG in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Sandoz Group AG.

Recent articles on PMLiVE featuring Sandoz Group AG

- PMLiVE
Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

The disease-modifying therapy is approved to treat all indications covered by Tysabri

- PMLiVE
Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE
Can the patient pathway provide a route to success?

Why pharma companies need to identify barriers and co-create solutions along the patient pathway to ensure their new products reach the patients who need them

- PMLiVE
Changing an organisation’s microfoundations – why capabilities count

Today and tomorrow, it’s what you can and can’t do that counts

- PMLiVE
Novartis to separate generic drugs division Sandoz to create standalone company

The spin-off will allow shareholders to participate fully in the potential future upside of both companies

- PMLiVE
Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

The initiative wants to increase the global use of biosimilars by at least 30% by 2030

- PMLiVE
Teva reaches $925,000 settlement to resolve drug price-fixing claims

Last year, the US Department of Justice charged Teva for conspiring with competitors in a generic drug price-fixing probe

- PMLiVE
Back to the future

Five years ago, an influential book used Darwin’s ideas to predict the future of the industry – how did that work out?

- PMLiVE
FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

Agency is due to make a decision for the approval by May 2021

Novartis day
Novartis donates malaria drug for COVID-19 clinical trials

Hydroxychloroquine will be evaluated for efficacy against novel coronavirus disease

- PMLiVE
Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

Novartis day
Novartis raises 2019 guidance as new products gather speed

Cosentyx leads the way with 25% growth

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links